120 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. Written … litigation under federal and state statutes, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially
6-K
EX-99.1
OBSVF
ObsEva SA
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act
6-K
EX-99.1
OBSVF
ObsEva SA
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect
6-K
EX-99.1
OBSVF
ObsEva SA
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE.
Section 13.06 Treatment
6-K
EX-99.3
rd2waoo
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
mpwxnwljqfkqgv2lg3r
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
qlz360usa2r
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
j307ygckszr6
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
890nhn7d
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
wg660 urar
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
zs6d8ia dimpb
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
nftqcuws
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K
EX-99.1
emwxq7m671489
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
m4h 15n1rqpzykq
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
bqufve axve75068
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
pvh3hdht
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
db05k qtl4ap
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.1
kqbwuxw5t9pd197c
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.2
bk84d
27 Jul 22
ObsEva Announces Corporate Updates
7:03am